Respiratory symptoms among HIV-seropositive individuals.
OBJECTIVE
Recent evidence suggests that chronic or latent viral infection may be an important predisposing factor in the development of COPD among smokers. As such, understanding if HIV-seropositive smokers are at heightened risk for respiratory symptoms may have relevance with regard to COPD pathogenesis. The current study was done to systematically identify the prevalence of respiratory symptoms among an HIV-seropositive population and to identify associated clinical features.


METHODS
Cross-sectional analysis at an academic medical center.


METHODS
Three hundred twenty-seven HIV-seropositive individuals without a history of AIDS-related pulmonary complications. Fifty-two HIV-negative individuals with a similar age and smoking history served as a comparison group.


METHODS
Administration of the American Thoracic Society Division of Lung Diseases respiratory questionnaire, and pulmonary function studies.


RESULTS
Respiratory symptoms including dyspnea (41.6% vs 7.7%), cough (40% vs 25%), and phlegm production (41.9% vs 23.1%) were extremely common in the HIV-group and significantly more common than in the HIV-negative group. Current or prior cigarette smoking was the most important predictor of respiratory symptoms among the HIV-seropositive group. The use of the antiretroviral agent lamivudine was associated with a significant reduction in dyspnea.


CONCLUSIONS
HIV-seropositive individuals are at increased risk for the development of respiratory symptoms even prior to the onset of AIDS-related pulmonary complications. This may reflect a heightened susceptibility to the effects of cigarette smoking.
Diaz
Philip T
PT
Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
Wewers
Mark D
MD
Pacht
Eric
E
Drake
Janice
J
Nagaraja
Haikady N
HN
Clanton
Thomas L
TL
D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use; D003371:Cough; D003430:Cross-Sectional Studies; D004417:Dyspnea / Q000188:drug therapy / Q000209:etiology; D006679:HIV Seropositivity / Q000188:drug therapy / Q000503:physiopathology*; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use; D012129:Respiratory Function Tests; D012137:Respiratory System / Q000503:physiopathology*; D012907:Smoking; D011795:Surveys and Questionnaires
D019380:Anti-HIV Agents; D019259:Lamivudine